Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms

Abroad (travel likely)Recruiting

Conditions

Myeloproliferative Neoplasm

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Inserm U1287, Villejuif, Île-de-France Region, France
Contact: Study coordinator (Isabelle Plo, PhD) · isabelle.plo@gustaveroussy.fr · +33 1 42 11 54 93
Contact: Study coordinator (Léa Durix) · lea.durix@gustaveroussy.fr · +33 1 42 11 54 93
Contact: Principal Investigator (Florence Pasquier, MD, PhD)

Study leads

Florence Pasquier, MD,PhD
Principal Investigator
florence.pasquier@gustaveroussy.fr

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic Therapy

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Phoenix, United States

A Study of BGB-11417 in Participants With Myeloid Malignancies

Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasm

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Tampa, United States

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Duarte, United States

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

Essential Thrombocythemia (ET) · Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) · Myeloproliferative Neoplasms (MPN)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Sydney, Australia · Sydney, Australia